Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease
London, UK, 16 March 2021 - Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support the development of a novel disease-modifying antibody therapy for Huntington’s disease (HD). The grant will support Alchemab in its pioneering collaboration with Medicines Discovery Catapult.
Alchemab Therapeutics 55-56 Russell Square London WC1B 4HP |
Meditrina Building 260 Babraham Research Campus Cambridge CB22 3AT |
© 2021 Alchemab. All rights reserved.